Patents Examined by Patricia Duffy
  • Patent number: 10711044
    Abstract: The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of light-activated ion channels.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: July 14, 2020
    Assignees: Massachusetts Institute of Technology, The Governors of the University of Alberta
    Inventors: Nathan Klapoetke, Brian Yichiun Chow, Edward Boyden, Gane Ka-Shu Wong, Yongku Peter Cho
  • Patent number: 10702482
    Abstract: The present invention relates to a slow-release solid oral nutraceutical and/or pharmaceutical composition comprising: a core containing a donor of methyl groups and at least one pharmaceutically acceptable excipient, and an outer coating containing shellac and/or a pharmaceutically acceptable salt thereof, magnesium stearate, and at least one pharmaceutically acceptable excipient. The coating of said solid oral composition allows the donor of methyl groups, preferably SAMe and/or a pharmaceutically acceptable salt thereof, to cross intact the gastric barrier and release the same in a continuous and complete manner along the entire digestive tract.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: July 7, 2020
    Assignee: GNOSIS SPA
    Inventors: Daniele Giovannone, Niccolò Miraglia, Marco Berna
  • Patent number: 10675358
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 9, 2020
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Bolt Biotherapeutics, Inc.
    Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
  • Patent number: 10668164
    Abstract: The present invention relates generally to glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a spacer containing ((2-oxoethyl)thio)). In an aspect the invention provides oxo-eT linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a ((2-oxoethyl)thio) spacer having the formula (I): (I) wherein: A is a group (C?X)m wherein X is S or O and m is 0 or 1; B is a bond, O, or CH2; and when m is 0, B can also be (C?O); R is a C2-C16 alkylene, C2-C16 heteroalkylene, NH—C(?O)—C2-C16 alkylene, or NH—C(?O)—C2-C16 heteroalkylene, wherein said alkylene and heteroalkylene are optionally substituted by 1, 2 or 3 groups independently selected from COOR? where R? is selected from H, methyl, ethyl or propyl. The invention further relates to immunogenic compositions comprising such glycoconjugates, and to methods for the preparation and use of such glycoconjugates and immunogenic compositions.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: June 2, 2020
    Assignee: Pfizer Inc.
    Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
  • Patent number: 10639309
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: May 5, 2020
    Assignee: Pfizer Inc.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
  • Patent number: 10632049
    Abstract: The present disclosure provides a cosmetic including a cosmetic composition having low viscosity, a receiving member in which the cosmetic composition having low viscosity is received, and a film forming member which covers an opening of the receiving member. By the use of the elastic film forming member, the cosmetic of the present disclosure may provide convenience of carrying with, reduce the container volume, and increase an amount of cosmetic composition contained, as compared to sponge impregnation material cosmetics.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: April 28, 2020
    Assignee: LG HOUSEHOLD & HEALTH CARE LTD.
    Inventors: Byeong-Gyu Park, Sung-Soo Kang, Min-Ji Cha, Sang-Wook Park
  • Patent number: 10633639
    Abstract: Chimeric polypeptides useful as immunogens for inducing protective immune responses and neutralizing antibodies against Shiga toxin (Stx) in mammals. More specifically, chimeric polypeptides having a monomer of the homopentameric B subunit of the Shiga 2 toxin fused to the N-terminus of a monomer of Brucella lumazine synthase, and to oligomeric protein complexes formed from said chimeric polypeptides. Polynucleotides and vectors encoding said chimeric polypeptides, transgenic cells having said polynucleotides and vectors, pharmaceutical compositions, such as a vaccine, having said chimeric polypeptides and chimeric polynucleotides, antibodies which bind to the chimeric polypeptides, a method for obtaining antibodies which bind specifically to the subunit B of the Shiga 2 toxin and methods of lowering the bacterial load of enterohemorrhagic Escherichia coli in mammals, which can be used for prevention of inter alia, hemolytic-ureic syndrome (HUS), are also provided.
    Type: Grant
    Filed: May 26, 2014
    Date of Patent: April 28, 2020
    Assignees: IMMUNOVA S.A., CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS
    Inventors: Fernando Alberto Goldbaum, Vanesa Zylberman, Patricio Oliver Craig, Giselle Ghersi, Marina Sandra Palermo, Maria Pilar Mejias, Leticia Veronica Bentancor
  • Patent number: 10624923
    Abstract: Disclosed are pharmaceutical compositions and related methods for treating a subject with a viral or retroviral infection. The disclosed compositions and methods comprise and utilize an effective amount of one or more vanadium-containing compounds and an effective amount of one or more sulfonylureas. In certain embodiments, the viral infection is human immunodeficiency virus (HIV) and the compositions and methods improve one or more immunologic cellular parameters, such as viral load, CD4 counts and CD4/CD8 lymphocyte cell ratios in a subject. Also disclosed are methods of improving one or more immunologic cellular parameters that are associated with viral infections such as HIV in a subject, including viral load, CD4 counts and CD4/CD8 lymphocyte cell ratios.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: April 21, 2020
    Inventor: Enrique G. Gutierrez
  • Patent number: 10610491
    Abstract: A liquid composition which comprises an organic liquid diluent and a hydroxyalkyl methylcellulose which has a certain distribution of substituted hydroxyalkoxyl groups and unsubstituted hydroxyalkoxyl groups is stable over an extended time period. In the hydroxyalkyl methylcellulose hydroxyalkoxyl groups are classified into a fraction (A) and a fraction (B), wherein fraction (A) represents the sum of all molar fractions of substituted hydroxyalkoxyl groups having hydroxyl groups substituted further with methoxyl groups and fraction (B) represents the sum of all molar fractions of unsubstituted hydroxyalkoxyl groups having hydroxyl groups not substituted further with methoxyl groups and wherein the ratio fraction (A)/fraction (B) is at least 0.30. The liquid composition is useful for preparing a solid dispersion comprising at least one active ingredient in at least one hydroxypropyl methylcellulose by spray-drying.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: April 7, 2020
    Inventors: Meinolf Brackhagen, Matthias Knarr, Roland Adden
  • Patent number: 10613085
    Abstract: The present invention is directed to monoclonal antibodies and antigen-binding portions thereof, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies or portions thereof are characterized by the sequences of the 6 CDR of the variable regions of the heavy and light chains. These antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X especially in a biological sample without purification of the capsular polysaccharides. The invention also concerns said monoclonal antibodiesor adequate portions thereofin different diagnostic tests and methods, in order to detect NmX. The invention discloses also a rapid diagnostic test for detecting NmX in a biological fluid.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: April 7, 2020
    Assignee: INSTITUT PASTEUR
    Inventors: Muhamed-Kheir Taha, Alain Agnememel
  • Patent number: 10610580
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: April 7, 2020
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Patent number: 10603280
    Abstract: The invention relates to solid medicinal forms containing at least one active ingredient and at least one pharmaceutically compatible, water soluble drying agent which is selected from the group consisting of trimagnesium dicitrate and/or calcium chloride, the solid medicinal form having a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less. The invention also relates to solid medicinal forms containing a moisture-sensitive active ingredient and trimagnesium dicitrate.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: March 31, 2020
    Assignee: Losan Pharma GmbH
    Inventors: Peter Gruber, Dirk Spickermann
  • Patent number: 10603279
    Abstract: The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: March 31, 2020
    Assignee: The University of Liverpool
    Inventors: Marco Norman Giardiello, Thomas Oliver McDonald, Andrew Owen, Steven Paul Rannard, Philip John Martin, Darren Lee Smith, James Long
  • Patent number: 10603369
    Abstract: Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 31, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Barbara Baudner, David Skibinski, Manmohan Singh, Derek O'Hagan
  • Patent number: 10596238
    Abstract: Embodiments of the invention are directed to fibrillar adjuvants. Epitopes assembled into nanofibers by a short synthetic fibrillization domain elicited high antibody titers in the absence of any adjuvant.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: March 24, 2020
    Assignee: The University of Chicago
    Inventors: Joel H. Collier, Jai Simha Rudra
  • Patent number: 10588857
    Abstract: The invention provides oral vaccine formulations which deliver an antigen in the vicinity of the distal ileum and the area of the ileal Brake and/or the appendix. These vaccines are useful in the treatment and/or prevention of variety of disorders, including viral and bacterial infections and cancers. Related methods of treatment which use the oral vaccine formulations of the invention are also provided.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 17, 2020
    Assignee: Therabiome, LLC
    Inventors: Jerome J. Schentag, Mohan Kabadi
  • Patent number: 10590165
    Abstract: There is disclosed a Dolastatin derivative, conjugated to an antibody, comprising a Dolastatin derivative moiety of Formula IV.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: March 17, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Zhenwei Miao, Gang Chen, Tong Zhu, Alisher B. Khasanov, Dylan Deng, Hong Zhang
  • Patent number: 10584370
    Abstract: Disclosed herein are methods for screening clinical or biological samples to determine the presence of L-form bacteria within the sample. Methods include contacting a sample to a liquid growth medium and incubating the liquid growth medium at a temperature lower than 37 degrees C. The liquid growth medium is monitored for L-form bacterial growth. An amount of the liquid growth medium is transferred as an inoculant to a solid growth medium, and the solid growth medium is incubated under conditions that maintain a hydrated state of the inoculant to enable the L-form bacteria to efficiently interface with the solid growth medium and continue to grow.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: March 10, 2020
    Assignee: Soft Cell Biological Research, LLC
    Inventor: John Brent Hunt
  • Patent number: 10577412
    Abstract: The technology provided herein relates to novel human antibodies against Plasmodium parasites, in particular against the malaria parasite Plasmodium falciparum. The present disclosure pertains to antibodies against apical membrane antigen 1 (AMA-1). These antibodies have high affinity e.g. to Plasmodium falciparum schizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: March 3, 2020
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Rolf Fendel, Stefan Barth, Rainer Fischer, Andreas Reimann, Dominika Maskus, Torsten Klockenbring
  • Patent number: 10570192
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: February 25, 2020
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen